Emerging Markets Earnings: BMS Eyes HCV In Japan, China HIV Sales Slow
This article was originally published in PharmAsia News
Bristol-Myers Squibb provides few insights into emerging markets earnings, though it fills in some color on HCV in Japan and China HIV sales.
You may also be interested in...
The big pharma posted strong results in the third quarter for its oncology franchise, but looks to its future in cancer immunotherapy to bring about growth post-patent losses.
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.
Southeast Asia in 2014 saw a continued push by several nations in the region to ink a Trans-Pacific Partnership pact that would potentially have a major impact on biological drugs. Also manufacturing and distribution saw a leap in the hub of Singapore as governments in the region ramped-up health spending.